Report fraud and other complaints: MDH Complaints and Allegations Form
On this page
How to use these dashboards
Reporting Snapshot
New Drug Reports
Price Growth—Five Year Price Analysis
Price Growth—Comparative Price Change
Go back
Return to the Prescription Drug Price Transparency Data & Dashboards home page.
The dashboards include data submitted to MDH from January 2022 through March 2025.
Some data have been withheld to protect trade secrets or because a determination regarding the trade secret designation has not been finalized.
Visit the Public Input page to provide feedback on the dashboards, share your experiences, or suggest where MDH should focus its Prescription Drug Price Transparency work.
Explore the number and types of reports submitted to MDH under the New Drug and Price Growth provisions of the Prescription Drug Price Transparency Act.
Estimates of health care claims and spending in Minnesota are derived from the Minnesota All Payer Claims Database (MN APCD). They should be viewed as underestimates, as data for some self-insured employers, some Medicare FFS enrollees, and certain individuals with federal coverage are not collected.
Explore data submitted via New Drug reports. Use the therapeutic class filer to see trends in highly priced new drugs by type of treatment.
Note: The Percent Average Price—or % Price of Equivalent Products—takes the Wholesale Acquisition Cost (WAC) at data of introduction of the reported drug and compares it to the average WAC of all equivalent drugs on the same date. A figure of 100% would mean that the reported drug's WAC at introduction was exactly the average of the WACs of all the other equivalent drugs on the market. Where there is no Percent Average Price given, that means there were no equivalent drugs on the market, which is generally the case for brand drugs.
Explore the yearly and cumulative price increases of reported Price Growth drugs. Filter the data to see trends by manufacturer.
Compare the change in price for reported Price Growth drugs against the change in price of equivalent products in a drug family or against other drugs for which the manufacturer has increased prices. Filter the data by manufacturer, drug family, and National Drug Code (NDC).